New combo therapy aims to shrink untreatable liver tumors
NCT ID NCT07511504
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment for people with advanced liver cancer that cannot be surgically removed. The treatment combines a type of internal radiation (Y-90) with two immunotherapy drugs (durvalumab and tremelimumab) and a targeted therapy pill (zanzalintinib). The goal is to see if this combination can stop the cancer from growing for at least 6 months. About 40 adults with liver cancer that has spread locally will participate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an IDO1 inhibitor boost immunotherapy against liver cancer?
- AI takes on liver cancer: could a computer help pick the right immunotherapy?
- Immunotherapy combo tested against untreatable liver cancer
- New drug zanzalintinib tested for advanced liver cancer
- Liver cancer drug combo shows promise in large trial
- New hope for liver cancer patients with cirrhosis? tiny trial tests drug duo